Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSP70 Vaccine in High-Risk Breast Cancer
NCT00027131Phase 2Terminated
- Sponsor
- UConn Health
- Start
- Dec 2000
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AG-858 in breast cancer, sponsored by UConn Health. Primary endpoint: Tumor-specific T cell response. Started Dec 2000; status: terminated.
02
Drugs
AG-858
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00027131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027131.